Merck KGaA MKKGY
33.67 USD -0.04 (-0.12%)
Nov 10, 2026, 3:59 PM EST
33.36 Day range 33.98
23.73 52-week range 34.19
- YTD
- +17.40%
- 1 year
- +32.09%
- Market cap
- 73.19B
- EPS (ttm)
- 1.27
- P/E ratio
- 26.51
- YTD return
- +17.40%
- 1-year return
- +32.09%
- Volume
- 2.45K
- Avg volume
- 87.75K
- Open
- 33.44
- Previous close
- 33.71
- Day's range
- 33.36 – 33.98
- 52-week range
- 23.73 – 34.19
- Earnings date
- Nov 12, 2026
No chart data for this range yet.
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate 0.46.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | 0.46 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.47 | 0.26 | -0.21 | -44.68% |
| May 13, 2026 | Mar 31, 2026 | 0.45 | 0.59 | +0.14 | +31.11% |
| Mar 5, 2026 | Dec 31, 2025 | 0.47 | 0.28 | -0.19 | -40.43% |
| Nov 13, 2025 | Sep 30, 2025 | 0.54 | 0.81 | +0.27 | +50.00% |
| Aug 7, 2025 | Jun 30, 2025 | 0.51 | 0.57 | +0.06 | +11.76% |
News
Why Is Silence Therapeutics Stock Skyrocketing Monday? 
Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal 
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover 
Bio-Techne To Pay Termination Fee Of $230.5M To Merck KGaA In Event That Deal Isn't Consummated; Merck KGaA To Pay Fee Of $576.1M If Deal Terminated 
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday 
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal 
CORRECTION: Germany's Merck KGaA To Acquire Bio-Techne At $73 Per Share In Cash At EV $11.3B; Deal Expected To Be Immediately Sales Accretive And EBITDA Pre Margin Post-Closing And EPS Pre Accretive By Year 3 Post-Closing 
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges 
'Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say' - Reuters 
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times
Your note
Sign in to keep a note on MKKGY — it syncs with the Stock Master app.